US Stem Cell Inc (USRM)

[Dragon Lady]

LOL quote, "I just hope they stop dilution"

Well, there's no sign of that occurring since they diluted out over 65 MILLION shares in just Jan, Feb and early March of 2015, this year.

Also, they've not been public traded for 10 yrs, but only 7. Their IPO was in 2008 and for all intents and purposes was a dismal failure. They barely lasted 1 yr on the Nasdaq before being de-listed and relegated to the OTC where they've diluted out from less than 20 MILLION share O/S in 2008, to well over 700 MILLION shares today, April of 2015 (and yes, their market cap has massively collapsed, it has NOT remained even close to the same as it was at the time of their IPO, 100% not true).

http://venturebeat.com/2008/02/20/bioheart-a-new-record-for-ipo-futility/

http://venturebeat.com/2008/02/19/three-yards-and-a-cloud-of-dust-bioheart-makes-it-across-the-ipo-goal-line-but-with-little-to-show-for-its-struggles/

http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aBNETYMPJCg4

The company has never made a dime of profit, never been even remotely close to cash flow positive (and is still not to this day), and has over $118 MILLION in sunk capital while never producing so much as ONE CENT in ROI to the common shares.

The common stock has lost essentially 99.99% of it's value since its IPO and essentially 99% or more of its common value since the present CEO took over in mid 2010. When the present CEO took over in mid 2010, there were about 30 MILLION shares of common stock O/S, today there is over 700 MILLION.

There has been numerous, numerous so called "new business plans" that were issued in PR's over the years- and none that I'm aware of have ever amounted to a hill of beans- just more dilution and an ever collapsing common share price.

$5.00 to .008 cents is a literal 99.99% loss to the common shares.

From the latest, most recent filed 10-K, covering to early March of 2015- one can see that the company is still MASSIVELY diluting its common shares, that they are cash broke finishing 2014 with a grand total of $34K total dollars to their name despite numerous toxic, convertible debt deals done all during the year to finance their operations. They took a greater loss from operations in yr 2014 than they did in yr 2013 and that's despite hacking out over $500K from their R&D budget and they've not conducted a major FDA level clinical trial since the 2009/2010 time frame, now over 5 yrs ago, due to "lack of funding" in their own words- SEE 10-K FACTS.

http://www.sec.gov/Archives/edgar/data/1388319/000114544315000378/bioheart_10k.htm

PAGE F-34, latest filed 10-K, NO abatement to mass share dilution being used to pay common bills and debt and also qty-3 more toxic, floorless, convertible debt deals done in just Jan and Feb of 2015 for pittances of survival cash- as they are so cash broke:

"Subsequent stock issuances

In January 2015, the Company issued 4,783,568 shares of its common stock in settlement for services, provided 14,299,567 shares of its common stock in settlement of $49,500 of outstanding convertible notes payable, and $2,981 accrued interest and 2,096,450 shares of its common stock for net proceeds of $16,118 from equity drawdown under the Magna Purchase Agreement.

In February 2015, the Company sold an aggregate of 1,443,656 shares of its common stock for net proceeds of $16,270. In connection with the stock sale, the Company issued an aggregate of 1,443,656 warrants to purchase the Company’s common stock for five years at $0.01127 per share. In addition, the Company issued 20,219,367 shares of its common stock in settlement of $132,500 of outstanding convertible notes payable and $2,520 accrued interest and 16,556,976 shares of its common stock for net proceeds of $135,645 from equity drawdown under the Magna Purchase Agreement.

In March 2015, the Company issued 6,185,432 shares of its common stock in settlement of $25,000 of outstanding convertible notes payable and $1,226 accrued interest. In addition, the Company issued 635,357 shares of its common stock as true up shares relating to the February 2015 equity drawdown under the Magna Purchase Agreement."

They're not reducing dilution, LOL. 65 MILLION shares plus (add those numbers up above) in just less than the first 3 months of 2015. They live off of dilution to keep from insolvency and BK, it's as simple as that IMO.

Also, they live off of using toxic, convertible debt- which in turn, as the price drops as it has been- gets just that much more dilutive, death spiral dilutive IMO.

2015 toxic notes already this year- no abating of this dilutive financing as is "claimed", NONE.

PAGE F-34 again:

"Subsequent financing

On January 7, 2015, the Company entered into a Securities Purchase Agreement with KBM Worldwide, Inc. (“KBM”), for the sale of an 8% convertible note in the principal amount of $38,000 (the “Note”).

The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on October 9, 2015. The Note is convertible into common stock, at KBM’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.

On January 28, 2015, the Company entered into a Securities Purchase Agreement with Fourth Man, LLC., for the sale of an 9.5% convertible note in the principal amount of $25,000 (the “Note”).

The Note bears interest at the rate of 9.5% per annum. All interest and principal must be repaid on January 27, 2016. The Note is convertible into common stock, at Asher’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts

On February 19, 2015, the Company entered into a Securities Purchase Agreement with Vis Vires Group, Inc. (“VIS”), for the sale of an 8% convertible note in the principal amount of $38,000 (the “Note”).

The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on November 23, 2015. The Note is convertible into common stock, at VIS’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
F-35"

Toxic, desperation financing notes in amounts of $25K and $38K cause they're supposedly almost cash flow positive, LOL??? Right.